FWM
AUPH icon

Focused Wealth Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Focused Wealth Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,000
Closed -$48.4K – 1036
2023
Q2 		$48.4K Buy
+5,000
New +$51.9K 0.01% 309

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Focused Wealth Management's AUPH Position: Q3 2023 in Review

Focused Wealth Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2023, closing a stake of 5,000 shares — an estimated $48.4K sold.

Focused Wealth Management first reported a position in AUPH in Q2 2023 and held it in 1 quarter. The position peaked at $48.4K in Q2 2023. 198 funds tracked by Wall St. Rank hold AUPH as of Q3 2023.

  • Focused Wealth Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Focused Wealth Management sold 5,000 Aurinia Pharmaceuticals shares in Q3 2023, an estimated $48.4K.
  • Focused Wealth Management first reported a position in Aurinia Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Focused Wealth Management's Aurinia Pharmaceuticals position peaked at $48.4K in Q2 2023.
  • 198 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2023.

Based on Focused Wealth Management's 13F filing for Q3 2023, filed 1 Nov 2023.